Trial · NCT00856206
Adverse events96
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 96
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Injection site erythema | General disorders | Placebo | 1 | 330 | 1 |
| other | Injection site erythema | General disorders | Rilonacept 160 mg | 61 | 985 | 195 |
| other | Accidental overdose | Injury, poisoning and procedural complications | Placebo | 20 | 330 | 21 |
| other | Accidental overdose | Injury, poisoning and procedural complications | Rilonacept 160 mg | 54 | 985 | 61 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Placebo | 20 | 330 | 41 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Rilonacept 160 mg | 65 | 985 | 85 |
| other | Pain in extremity | Musculoskeletal and connective tissue disorders | Placebo | 15 | 330 | 21 |
| other | Pain in extremity | Musculoskeletal and connective tissue disorders | Rilonacept 160 mg | 52 | 985 | 74 |
| other | Headache | Nervous system disorders | Placebo | 26 | 330 | 45 |
| other | Headache | Nervous system disorders | Rilonacept 160 mg | 90 | 985 | 169 |
| serious | Anaemia | Blood and lymphatic system disorders | Placebo | 0 | 330 | 0 |
| serious | Anaemia | Blood and lymphatic system disorders | Rilonacept 160 mg | 2 | 985 | 2 |
| serious | Acute coronary syndrome | Cardiac disorders | Placebo | 1 | 330 | 1 |
| serious | Acute coronary syndrome | Cardiac disorders | Rilonacept 160 mg | 1 | 985 | 1 |
| serious | Atrial fibrillation | Cardiac disorders | Placebo | 0 | 330 | 0 |
| serious | Atrial fibrillation | Cardiac disorders | Rilonacept 160 mg | 2 | 985 | 2 |
| serious | Myocardial infarction | Cardiac disorders | Placebo | 0 | 330 | 0 |
| serious | Myocardial infarction | Cardiac disorders | Rilonacept 160 mg | 2 | 985 | 2 |
| serious | Gastric ulcer haemorrhage | Gastrointestinal disorders | Placebo | 0 | 330 | 0 |
| serious | Gastric ulcer haemorrhage | Gastrointestinal disorders | Rilonacept 160 mg | 1 | 985 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00856206/events